On March 16, 2021, pursuant to the Agreement and Plan of Merger, dated as of December 14, 2020, by and among Anchiano Therapeutics Ltd. (Anchiano), CMB Acquisition Ltd. (Merger Sub), and Chemomab Ltd. (Chemomab), Anchiano completed the previously announced merger transaction, pursuant to which Merger Sub merged with and into Chemomab, with Chemomab surviving such merger as a wholly owned subsidiary of Anchiano (the Merger). In connection with the Merger, on March 16, 2021, Anchiano changed its name to Chemomab Therapeutics Ltd. In accordance with the Merger Agreement, Stanislav Polovets, Ruth Alon and Isaac Kohlberg resigned from the Board and any respective committees of the Board of which they were members. The resignations were not the result of any disagreements with Anchiano relating to its operations, policies or practices. In accordance with the Merger Agreement, on March 16, 2021, effective at the Effective Time, the following individuals were appointed to the Board as directors: Stephen Squinto, Adi Mor, Nissim Darvish, Joel Maryles, Alan Moses and Claude Nicaise. Following the Merger, the classes of the Board are as follows: Class I Directors, whose terms expire at the company's 2022 Annual Meeting: Stephen Squinto, Nissim Darvish and Joel Maryles. Class II Directors, whose terms expire at the Company's 2023 Annual Meeting: Neil Cohen and Claude Nicaise. Class III Directors, whose terms expire at the Company's 2024 Annual Meeting: Adi Mor and Alan Moses. Stephen Squinto will serve on the Board as chairman upon the consummation of the Merger. Squinto currently serves on the boards of directors of Passage Bio Inc., SpringWorks Therapeutics Inc., and several private companies. Mor is a co-founder of Chemomab and has served as Chemomab's Chief Executive Officer, Chief Scientific Officer, member of Chemomab's board of directors since its formation in 2011. Darvish currently serves as a director of 9 Meters Biopharma Inc. and several private companies. Maryles currently serves on the board of directors and as the Chairman of Remuneration Committee of Jefferies International Ltd., since 2016. Moses currently serves on the board of directors of BioFabUSA, since 2018. Nicaise currently serves on the board of directors and as the Chairman of the Compensation Committee of Sarepta Therapeutics Inc., since 2015, as well as on the board of directors of Mynoryx Therapeutics, since 2017. Neil Cohen has served as a member of Anchiano's board of directors since April 2020 and as Anchiano's interim Chief Executive Officer from October 2020 until the consummation of the Merger. In connection with the closing of the Merger, Joel Maryles, Alan Moses and Claude Nicaise were appointed to the audit committee of the Board. Joel Maryles was appointed as the chairperson of the audit committee and is a financial expert under the rules of the SEC. In connection with the closing of the Merger, Nissim Darvish and Neil Cohen were appointed to the compensation committee of the Board, and Nissim Darvish was appointed the chair of the compensation committee. In connection with the closing of the Merger, Neil Cohen and Joel Maryles were appointed to the nominating and corporate governance committee of the Board, and Neil Cohen was appointed the chair of the nominating and corporate governance committee. In accordance with the Merger Agreement and an action of the Board, on March 16, 2021, the Board appointed Adi Mor as the company's Chief Scientific Officer and Aaron Aharon as the company's Chief Medical Officer, each effective as of the closing of the Merger and to serve at the discretion of the Board. Arnon Aharon has served as Chemomab's Chief Medical Officer since January 2018.